IPCALAB IPCA Laboratories Q4 FY25 results (Jan–Mar 2025) and concall
Ipca Labs reported strong Q4 and FY25 results, with domestic business growing 11-12% and overall Ipca growth outpacing the market at 13.2%. Consolidated FY25 EBITDA margin reached 18.94%, exceeding guidance. The company is investing significantly in future growth with 4 new manufacturing facilities set to begin trial production in FY26. However, the API business saw muted growth, and the South African generic business experienced a significant decline due to lost tenders.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 2,355 | 2,245 | 2,247 |
| EBITDA | 441 | 463 | 429 |
| Net profit | 246 | 276 | 64 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
